More than 50 million! Huadong Pharmaceutical Co., Ltd. has entered into a technology related transaction of new drug datormycin

Huadong pharmaceutical: the company's manufacturing branch and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd intend to acquire the assets appraisal report of the project of technical value appraisal of datomycin new drug owned by Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd announcement date: June 13, 2016 Huadong Pharmaceutical Co., Ltd manufacturing branch, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd The company intends to acquire the project of technology value evaluation of datomycin new drug owned by Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd assets evaluation report report Kunyuan evaluation report [2016] No 232 Kunyuan assets evaluation Co., Ltd Catalogue of June 1, 2016 Statement of certified public valuer Main body of the assets appraisal report............................................................................................. 5 I the entrusting party, the property right holding unit and other users of the appraisal report............................................................................................. 5 2 Purpose of the appraisal 7 Object and scope of the appraisal 8 IV type of value and its definition Vi appraisal assumption 9 Appraisal basis 10 VIII Evaluation method.............................................................................................. 11 IX evaluation process....................................................................... 13 X appraisal conclusion 14 Xi Special notes 14 12 Description of the restrictions on the use of the appraisal report 15 Annex to the assets appraisal report 17 Manufacturing branch of Huadong Pharmaceutical Co., Ltd and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd plan to acquire the technical value assessment project of datomycin new drug owned by Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd asset assessment report and statement of certified asset appraiser I in the implementation of the assets appraisal business, we abide by the relevant laws and regulations and the assets appraisal standards, abide by the principles of independence, objectivity and impartiality, according to the data collected in the practice process, the contents stated in the appraisal report are objective, and bear the corresponding legal responsibility for the rationality of the appraisal conclusion II The list of assets involved in the appraisal object shall be declared by the entrusting party and the property right holding unit and confirmed by their signatures; the responsibility of the entrusting party and relevant parties is to provide the authenticity, legality and integrity of the materials provided and to use the appraisal report properly III We have no existing or expected interest relationship with the appraisal object in the appraisal report; we have no existing or expected interest relationship with the relevant parties, and we have no prejudice against the relevant parties IV according to the requirements of relevant standards, we have conducted necessary on-site investigation on the appraisal object and the assets involved in the appraisal report; we have paid necessary attention to the legal ownership of the appraisal object and the assets involved The legal ownership information of the appraisal object and the assets involved has been checked, and the discovered problems have been disclosed truthfully However, the appraisal report cannot be used as the confirmation and guarantee of the legal ownership of the appraisal object and related assets V the analysis, judgment and conclusion in the appraisal report issued by us are limited by the assumptions and limiting conditions in the appraisal report The users of the appraisal report shall give full consideration to the assumptions, limiting conditions and special matters stated in the appraisal report and their impact on the appraisal conclusion 1 Kunyuan Assets Appraisal Co., Ltd manufacturing branch of Huadong Pharmaceutical Co., Ltd and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd to be acquired The project of technology value evaluation of datomomycin new drug owned by Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd asset evaluation report manufacturing branch of Huadong Pharmaceutical Co., Ltd and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd plan to acquire Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd Assets appraisal report of the technology value appraisal project of datomomycin new drug kunyuanpingbao [2016] No 232 Abstract: the following contents are extracted from the main body of the appraisal report To understand the details of the appraisal project and reasonably understand the appraisal conclusion, the main body of the appraisal report should be read carefully I the entrusting party and the property right holders and other users of the appraisal report The entrusting party of the current appraisal is the manufacturing branch of East China Pharmaceutical Co., Ltd (hereinafter referred to as "East China stock manufacturing branch") and Hangzhou Sino US East China Pharmaceutical Co., Ltd (hereinafter referred to as "Sino US East China company"), with the property right The owner is Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd (hereinafter referred to as "new drug research institute") According to the asset appraisal engagement letter, the other users of this appraisal report are the users of the appraisal report stipulated by national laws and regulations II Appraisal purpose: according to the resolution of 2016 interim shareholders' meeting of New Drug Research Institute on May 25, 2016 and the resolution of the board of directors of China US East China company on the transfer of new drug technology of daptomycin preparation on May 5, 2016, East China stock According to the agreement of the evaluation engagement letter, the evaluation agency was hired to evaluate the value of the "datomomycin new drug technology" involved in the economic behavior The purpose of this evaluation is to provide a reference for the value of "new drug technology of daptomycin" in this economic behavior III appraisal object and scope The appraisal object and scope are the "new drug technology of daptomycin" to be acquired by East China manufacturing branch and China US East China company, specifically including the production process, technology and related invention patents of daptomycin API and preparation products, as well as the government approval / license and other relevant materials and documents that should be obtained as a drug IV value type and its definition the value type of this appraisal is market value Market value refers to the estimated amount of the value of the normal and fair transaction of the appraised object on the benchmark date when the voluntary buyer and the voluntary seller act rationally without any coercion V the benchmark date is December 31, 2015 Vi appraisal method: according to the appraisal object, value type, data collection and other relevant conditions, the income method is adopted for this appraisal 7 Appraisal conclusion: on the basis of the appraisal assumptions disclosed in this report, the appraisal value of "datomomycin new drug technology" owned by the new drug research institute entrusted by East China Co., Ltd and China US East China company is 5032240.00 yuan (in words: Fifty three hundred and twenty two thousand four hundred yuan only) VIII Validity period of the appraisal conclusion: the validity period of the appraisal conclusion is one year, from the benchmark date of 2015 to December 31, 2016 IX special matters affecting the evaluation conclusion: in the evaluation of the value of "datomomycin new drug technology" owned by the new drug research institute, the company conducted necessary inspection on the legal ownership data and sources of the evaluation object and related assets provided by the new drug research institute, and the discovery Committee The manufacturers recorded in the drug registration approval (i.e production approval) issued by the State Food and drug administration obtained by the appraisal technology are Huadong Co., Ltd and Zhongmei Huadong Co., Ltd respectively, and the holders recorded in the new drug certificate are Huadong Co., Ltd., Zhongmei Huadong Co., Ltd and new drug research institute The new drug research institute has provided relevant agreements and instructions with the manufacturing branch of East China Co., Ltd and the East China company of China and the United States, and it is clear that the entrusted appraisal technology belongs to the new drug research institute It is the responsibility of new drug research institute, East China Co., Ltd and China US East China company to provide authentic, legal and complete legal ownership information about the assets The responsibility of the appraisers is to conduct necessary inspection on the information provided by new drug research institute, East China Co., Ltd and China US East China company The appraisal report cannot be used as the legal right of the appraisal object and related assets Confirmation and guarantee of property If the property owner does not own the ownership of the above-mentioned assets or has some restrictions on the ownership of the above-mentioned assets, the appraisal results of the above-mentioned assets will